Jun 24, 2024
by Suyeon Jang
HITS Co-Founder and CTO Named to Forbes 30 Under 30 Asia
We’re thrilled to announce that Dr. [Name], Co-Founder and Chief Technology Officer (CTO) of HITS, has been named to the Forbes 30 Under 30 Asia list in the Healthcare & Science category—the only Korean honoree in this field for 2024.
Each year, Forbes recognizes 30 rising leaders under the age of 30 across 10 industries—including healthcare, finance, and the arts—from 22 countries in the Asia-Pacific region.
In its profile, Forbes highlighted Dr. [Name]’s background as a Ph.D. graduate in chemistry from KAIST, and noted that he co-founded HITS in 2020, an AI-driven drug discovery startup. The publication also cited HITS’s development of software that accelerates the drug development process, along with strategic partnerships with major pharmaceutical companies such as LG Chem and HK inno.N.
This recognition not only underscores the impact of HITS’s technology in the healthcare space, but also reflects the talent and leadership driving innovation in Korea’s biotech ecosystem.
HITS Co-Founder and CTO Jaechang Lim Named to Forbes 30 Under 30 Asia
We’re proud to share that Jaechang Lim, Co-Founder and Chief Technology Officer (CTO) of HITS, has been named to the prestigious Forbes 30 Under 30 Asia list, representing the Healthcare & Science category. Notably, he is the only Korean selected in this category in 2024.
On March 15th, Forbes unveiled its annual “30 Under 30 Asia” list, recognizing 30 standout leaders under the age of 30 across 10 industries—including healthcare, finance, entertainment, and sports—across 22 countries in the Asia-Pacific region.
This year’s list also featured Japan’s youngest astronaut Ayu Yoneda, Olympic fencer Sang-uk Oh, and global K-pop group IVE. Among them, Dr. Lim stood out for his pioneering work in AI-powered drug discovery.
Forbes highlighted Lim’s academic background, noting that he earned his Ph.D. in Chemistry from KAIST, Korea’s top science and engineering university, and co-founded HITS in 2020 alongside his former advisor, Dr. Wooyoun Kim. Together, they launched the AI drug discovery platform HyperLab, which dramatically accelerates the drug development process.
HITS has since formed partnerships with major pharmaceutical companies including LG Chem and HK inno.N, and has secured over 6.5 billion KRW (~$5 million USD) in cumulative funding from top investors such as Korea Investment Partners and Capstone Partners.
Dr. Lim has published extensively in the field of generative AI for drug discovery, holding multiple patents and research papers. Under his leadership, HITS successfully launched HyperLab in August 2023. Within just six months, the platform had already gained hundreds of global users, further solidifying the company's position as a leader in digital transformation of drug development.
Reflecting on the recognition, Dr. Lim shared:
“It’s an incredible honor to be included among such outstanding individuals across various fields. I’ll continue dedicating myself to advancing AI technology that can lead to meaningful progress in drug development and contribute to a healthier future.”
We’re incredibly proud of Jaechang Lim, whose leadership and vision have been instrumental in shaping HITS’s global journey.
Congratulations on being named to Forbes 30 Under 30 Asia—a well-deserved recognition for an inspiring leader driving real impact in the world of AI-driven drug discovery.
Back to News